FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024893931> ?p ?o ?g. }

• W2024893931 endingPage "5388" @default.
• W2024893931 startingPage "5375" @default.
• W2024893931 abstract "A series of potent vascular endothelial growth factor R2 (VEGF-R2) tyrosine kinase inhibitors from a new indenopyrrolocarbazole template is reported. The structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones revealed an optimal R9 substitution with ethoxymethyl 19 (VEGF-R2 IC(50) = 4 nM) and isopropoxymethyl 21 (VEGF-R2 IC(50) = 8 nM) being the most potent inhibitors in the series. The VEGF-R2 activity was reduced appreciably by increasing the size of the R9 alkoxy group or by alpha-methyl branching adjacent to the ring. The combined R9 alkoxymethyl and N12 hydroxypropyl substitutions were required for potent VEGF-R2 activity, and the corresponding thioether analogues were weaker than their ether counterparts. Compound 21 (R9 isopropoxymethyl, CEP-5214) was identified as a potent, low-nanomolar pan inhibitor of human VEGF-R tyrosine kinases, displaying IC(50) values of 16, 8, and 4 nM for VEGF-R1/FLT-1, VEGF-R2/KDR, and VEGF-R3/FLT-4, respectively, with cellular activity equivalent to the isolated enzyme activity. Compound 21 exhibited good selectivity against numerous tyrosine and serine/threonine kinases including PKC, Tie2, TrkA, CDK1, p38, JNK, and IRK. To increase water solubility and oral bioavailability, the N,N-dimethylglycine ester 40 was prepared. In pharmacokinetic studies in mice and rats, increased plasma levels of 21 were observed after oral administration of 40. Compound 21 demonstrated significant in vivo antitumor activity in numerous tumor models and was advanced into phase I clinical trials as the water-soluble N,N-dimethylglycine ester prodrug 40 (CEP-7055)." @default.
• W2024893931 created "2016-06-24" @default.
• W2024893931 creator A5000331239 @default.
• W2024893931 creator A5015150163 @default.
• W2024893931 creator A5029840953 @default.
• W2024893931 creator A5030081188 @default.
• W2024893931 creator A5036665836 @default.
• W2024893931 creator A5043649507 @default.
• W2024893931 creator A5045981129 @default.
• W2024893931 creator A5051384592 @default.
• W2024893931 creator A5057166673 @default.
• W2024893931 creator A5057792134 @default.
• W2024893931 creator A5066909701 @default.
• W2024893931 creator A5069322702 @default.
• W2024893931 creator A5069806610 @default.
• W2024893931 creator A5072020818 @default.
• W2024893931 creator A5073482470 @default.
• W2024893931 creator A5086400213 @default.
• W2024893931 date "2003-10-31" @default.
• W2024893931 modified "2023-09-26" @default.
• W2024893931 title "A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055" @default.
• W2024893931 cites W1573363574 @default.
• W2024893931 cites W1720535299 @default.
• W2024893931 cites W175636503 @default.
• W2024893931 cites W1973918329 @default.
• W2024893931 cites W1977030165 @default.
• W2024893931 cites W1981202033 @default.
• W2024893931 cites W1982904703 @default.
• W2024893931 cites W1985712533 @default.
• W2024893931 cites W1992388470 @default.
• W2024893931 cites W1998241472 @default.
• W2024893931 cites W2000000541 @default.
• W2024893931 cites W2018206586 @default.
• W2024893931 cites W2022185380 @default.
• W2024893931 cites W2025717261 @default.
• W2024893931 cites W2028063515 @default.
• W2024893931 cites W2029245342 @default.
• W2024893931 cites W2058413420 @default.
• W2024893931 cites W2076057906 @default.
• W2024893931 cites W2082392313 @default.
• W2024893931 cites W2141046053 @default.
• W2024893931 cites W2146021659 @default.
• W2024893931 cites W2146787008 @default.
• W2024893931 cites W2168331927 @default.
• W2024893931 cites W3102812175 @default.
• W2024893931 doi "https://doi.org/10.1021/jm0301641" @default.
• W2024893931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14640546" @default.
• W2024893931 hasPublicationYear "2003" @default.
• W2024893931 type Work @default.
• W2024893931 sameAs 2024893931 @default.
• W2024893931 citedByCount "72" @default.
• W2024893931 countsByYear W20248939312012 @default.
• W2024893931 countsByYear W20248939312013 @default.
• W2024893931 countsByYear W20248939312014 @default.
• W2024893931 countsByYear W20248939312015 @default.
• W2024893931 countsByYear W20248939312016 @default.
• W2024893931 countsByYear W20248939312018 @default.
• W2024893931 countsByYear W20248939312019 @default.
• W2024893931 countsByYear W20248939312020 @default.
• W2024893931 countsByYear W20248939312022 @default.
• W2024893931 countsByYear W20248939312023 @default.
• W2024893931 crossrefType "journal-article" @default.
• W2024893931 hasAuthorship W2024893931A5000331239 @default.
• W2024893931 hasAuthorship W2024893931A5015150163 @default.
• W2024893931 hasAuthorship W2024893931A5029840953 @default.
• W2024893931 hasAuthorship W2024893931A5030081188 @default.
• W2024893931 hasAuthorship W2024893931A5036665836 @default.
• W2024893931 hasAuthorship W2024893931A5043649507 @default.
• W2024893931 hasAuthorship W2024893931A5045981129 @default.
• W2024893931 hasAuthorship W2024893931A5051384592 @default.
• W2024893931 hasAuthorship W2024893931A5057166673 @default.
• W2024893931 hasAuthorship W2024893931A5057792134 @default.
• W2024893931 hasAuthorship W2024893931A5066909701 @default.
• W2024893931 hasAuthorship W2024893931A5069322702 @default.
• W2024893931 hasAuthorship W2024893931A5069806610 @default.
• W2024893931 hasAuthorship W2024893931A5072020818 @default.
• W2024893931 hasAuthorship W2024893931A5073482470 @default.
• W2024893931 hasAuthorship W2024893931A5086400213 @default.
• W2024893931 hasConcept C101544691 @default.
• W2024893931 hasConcept C116073593 @default.
• W2024893931 hasConcept C146285616 @default.
• W2024893931 hasConcept C14858245 @default.
• W2024893931 hasConcept C150903083 @default.
• W2024893931 hasConcept C167734588 @default.
• W2024893931 hasConcept C170493617 @default.
• W2024893931 hasConcept C181389837 @default.
• W2024893931 hasConcept C184235292 @default.
• W2024893931 hasConcept C185592680 @default.
• W2024893931 hasConcept C193042331 @default.
• W2024893931 hasConcept C202751555 @default.
• W2024893931 hasConcept C207001950 @default.
• W2024893931 hasConcept C2776980637 @default.
• W2024893931 hasConcept C2777025900 @default.
• W2024893931 hasConcept C42362537 @default.
• W2024893931 hasConcept C502942594 @default.
• W2024893931 hasConcept C55493867 @default.
• W2024893931 hasConcept C71240020 @default.
• W2024893931 hasConcept C86803240 @default.

• next